Tag Archives: pralsetinib

Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More

COVID-19 research efforts are often characterized as a race between companies, a description that reflects the urgency to develop a vaccine for the novel coronavirus. The description is not quite right. A race has one winner and public health officials have said we’ll need multiple vaccines to address the global need. Vaccine developers have progressed […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

[Updated, 9/8/2020. See below.] A Blueprint Medicines drug for cancers that carry a certain genetic signature has received FDA approval, making it the latest targeted therapy to pass the regulatory bar this year. The late Friday decision for pralsetinib (Gavreto) covers non-small cell lung cancer (NSCLC). The drug was designed to address cancers characterized by fusions […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National blog main, National top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval. The two companies are partnering on the drug, pralsetinib, a targeted cancer therapy developed for lung and thyroid cancers characterized by abnormalities in a gene called RET. According to deal terms […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug

[Updated, 5/11/2020, 10:03 a.m. See below.] Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces […]

Posted in Boston blog main, Boston top stories, Indiana, Indiana blog main, Indiana top stories, National blog main, National top stories, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug